A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II

The purpose of this study is to compare the usual treatment, systemic therapy (chemotherapy), to the study treatment, paclitaxel administered through a tube in your belly plus systemic therapy (chemotherapy).

• Adults 18+ years of age
• Confirmed peritoneal carcinomatosis or gastric/gastroesophageal adenocarcinoma
• Must have received between 3-6 months of first line systemic treatment
• No evidence of bowel obstruction

• A diagnostic laparoscopy, a minimally invasive surgery performed under general anesthesia, in which small incisions are made in the abdomen
• Random assignment during the laparoscopy to receive either standard chemotherapy given intravenously (IV) alone, or standard IV chemotherapy plus paclitaxel delivered directly into the abdominal cavity
• Placement of an intraperitoneal port, a small device placed under the skin of the upper abdomen with a tube into the abdomen, for participants assigned to that group
• Imaging with computed tomography (CT), magnetic resonance imaging (MRI), or both
• Blood sample collection
• Additional diagnostic laparoscopies if needed